Drug Profile
Research programme: oxygen release enhancers - NormOxys Inc.
Alternative Names: OxyrensLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator NormOxys
- Class Small molecules
- Mechanism of Action Haemoglobin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hypoxia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Hypoxia in USA